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Available online 6 January 2016Complement activation contributes to inﬂammation in many diseases, yet it also supports physiologic apoptotic
cells (AC) clearance and its downstream immunosuppressive effects. The roles of individual complement compo-
nents in AC phagocytosis have been difﬁcult to dissect with artiﬁcially depleted sera. Using human in vitro sys-
tems and the novel antibody complement C1s inhibitor TNT003, we uncoupled the role of the enzymatic
activation of the classical pathway from the opsonizing role of C1q in mediating a) the phagocytosis of early
and late AC, and b) the immunosuppressive capacity of early AC.We found that C1s inhibition had a small impact
on the physiologic clearance of early AC, leaving their immunosuppressive properties entirely unaffected, while
mainly inhibiting the phagocytosis of late apoptotic/secondary necrotic cells. Our data suggest that C1s inhibition
may represent a valuable therapeutic strategy to control classical pathway activation without causing signiﬁcant
AC accumulation in diseases without defects in AC phagocytosis.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The complement system encompasses over 30 different proteins
participating in many different functions central for the maintenance
of both immune surveillance and of tolerance to self [1]. The initiator
of the classical complement cascade, the C1 complex, is activated by
C1q binding to antigen–antibody immune complexes. The C1 complex
is comprised of the opsonin C1q, and the serine proteases C1r and C1s.
Activation of C1s results in the cleavage of C4 and C2, allowing the as-
sembly of the classical pathway C3 convertase and cleavage of C3 into
C3a and C3b [2]. C3b can covalently bind to and opsonize pathogens,
triggering the activation of the downstream complement factors (C5–
C9), and formation of the membrane attack complex. Due to its central
role in both immune cell activation and immunological homeostasis, ab-
errant activation and/or hyperactivation of the complement cascade can
contribute to many different disease states [3,4]. Inﬂammation is a; CR2, complement receptor 2;
eat inactivated normal human
IL-1b, interleukin beta; IFN-a,
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. This is an open access article underconsequence of anaphylatoxin (C3a and C5a) release [5], with subse-
quent chemoattraction and activation of inﬂammatory cells [3] and/or
complement mediated cytotoxicity. In addition, complement affects
adaptive immunity by lowering the threshold of B cell activation via
complement receptor 2 (CR2) [6], and by sustaining Th1 differentiation
[7,8]. For these reasons, complement has been of central interest for
therapeutic intervention in many different areas, including autoimmu-
nity, inﬂammation, and transplantation [9,10].
In addition to responding to pathogens, classical complement
components facilitate apoptotic cell (AC) clearance by opsonization,
and also mediate immune suppression. This has been shown for C1q
[11–21] and for C3b/bi [22–26], which are implicated in the “waste dis-
posal” of dying cells [27]. Physiologic clearance of apoptotic cells takes
place very rapidly [28,29], and dead cell accumulation occurs only
under certain pathogenic conditions [30]. While efforts have been
made in vitro to dissect the relative importance of C1q from down-
stream complement components, artiﬁcial depletion of individual com-
plement components from normal sera has been shown to cause
reduction of other serum factors [15,31], and serum obtained from pa-
tients with complement deﬁciencies usually has elevated cytokines
and autoantibodies that may confound interpretation of the results
[32,33]. We reasoned that speciﬁc inhibition of enzymatic C1s activity
would be expected to leave C1q binding to AC unaffected, while
blocking classical pathway-mediated activation of C3. We therefore
employed the monoclonal antibody (mAb) C1s inhibitor, TNT003, as a
unique pharmacological tool to dissect the role of the enzymatic activa-
tion of the C1 complex from the opsonizing role of C1q in mediatingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ther, using this approach, we addressed whether C1s enzymatic activity
was required for the suppression of proinﬂammatory cytokine produc-
tion by stimulated macrophages [11,35–38].
2. Materials and methods
2.1. Apoptotic cells preparation
AC were prepared from Jurkat T cells (ATCC® Number: TIB-152) or
Ramos B cells (ATCC® Number: CRL-1596), as indicated. Early AC
(N65% Annexin V+PI−) were prepared by 12.5-25 mJ/cm2 UV irradia-
tion and incubation for 3–4 h at 37 °C inmedium supplementedwith 2%
heat inactivated FBS (Jurkat) or in the absence of serum (Ramos). Late
AC (N90% Annexin V+PI+) were prepared by 25 mJ/cm2 UV irradia-
tion and incubation overnight in the absence of serum.
2.2. C1q binding and C3b deposition assays
Normal human serum (NHS) was obtained from healthy donors fol-
lowing informed consent (HSD number 39712), and prepared in our
laboratory at the University of Washington, Seattle, WA. DMEMmedi-
um (HyClone) containing 10% NHS or heat inactivated sera (HI NHS)
was pre-incubated with isotype control mAb (mIgG2a F(ab’)2, True
North Therapeutics) or TNT003 (C1s inhibitor, F(ab’)2, True North Ther-
apeutics) at 45 μg/ml for 25–30min at 4 °C before incubationwith early
(N65% Annexin V+PI−) and late apoptotic Ramos (N90% Annexin
V+PI+) for 25–30min at 37 °C to allow: 1) C1q binding and/or 2) com-
plement activation and C3b deposition at 37 °C for 25–30 min. Possible
endotoxin contamination of the pepsin-digested F(ab’)2 Ab fragments
was removed via Celluﬁne ETclean S (Amsbio). The AC were then
washed, and stained with the mouse-anti-human C1q mAb (5 μg/ml,
Quidel) or the C3bmAb (clone 6C9; 2 μg/ml, Thermo Scientiﬁc), follow-
ed by goat-anti-mouse-FITC (Fcγ speciﬁc, to avoid detection of the
isotype control and TNT003 F(ab’)2; Jackson ImmunoResearch), and
subjected to ﬂow cytometry analysis (FACS Canto, BD Biosciences).
The mean ﬂuorescence intensity (MFI) values were used to compare
the average C1q binding and/or C3b deposition on early and late apo-
ptotic cells in the presence or absence of isotype control mAb or
TNT003 preincubation.
2.3. Phagocytosis assay
M-CSF-derived human macrophages (hMo) were differentiated
from circulating CD14+ precursors following magnetic isolation
(human CD14 microbeads; Miltenyi Biotech) in the presence of
50 ng/ml recombinant human M-CSF (Peprotech). hMo were utilized
at days 6–8 of differentiation. DMEM medium containing 10% NHS or
HI NHS was pre-incubated with isotype control mAb or TNT003 at
45 μg/ml for 25–30 min at 4 °C before incubation with ﬂuorescently la-
beled (Carboxyﬂuorescein succinimidyl ester, CFSE; Life Technologies)
early (N65%Annexin V+PI−) or late (N90% Annexin V+PI+) apopto-
tic Ramos cells for 25–30 min at 37 °C to allow complement activation
and deposition. The CFSE+ AC were then fed to the hMo at a 2:1
AC:Mo ratio for 20 min at 37 °C in a 48 well plate for phagocytosis to
ensue. Following 4 washes with cold PBS, the Mo were harvested with
the aid of trypsin–EDTA (HyClone), to both detach the adherent Mo
and to eliminate surface bound, non-internalized AC from the Mo. The
Mo were then washed in ﬂow cytometry buffer (PBS 1% BSA) and la-
beled with CD14-APC (clone HCD14; Biolegend) for ﬂow cytometry
analysis. Following gating on the total CD14+ Mo population, the Mo
CFSE mean ﬂuorescence intensity (MFI) gives a measure similar to the
phagocytic index (the number of AC engulfed by 1 macrophage), as
higher MFI correlates with the number of AC engulfed by the Mo. AC
phagocytosis was compared by calculating the percent inhibition ofCFSE MFI of the CD14+ gated Mo population by isotype control mAb
and by TNT003 over the untreated wells.
2.4. Cytokine suppression assay
M-CSF-derived hMo were utilized at days 6–8 of differentiation.
Early apoptotic Jurkat (N65% Annexin+PI−) were incubated with
10% NHS in presence or absence of isotype control mAb (45 μg/ml) or
TNT003 (45 μg/ml) for 25–30min at 37 °C. The ACwerewashed and in-
cubated before addition to the hMo at a 4:1 AC:Mo ratio in serum free
medium (X-Vivo-10; Lonza) to avoid interference by FBS-derived latent
TGF-b [37]. At the same time of AC addition, hMowere stimulated with
the Toll-like receptor 4 (TLR4) agonist lipopolysaccharide (LPS;
1 ng/ml) in the presence or absence of AC, and left overnight in culture
(18–20 h) before harvesting the supernatants for proinﬂammatory cy-
tokinemeasurements (TNF, IL-6, and IL-1b) by ELISA. The following an-
tibodies were used as capture and detection of IL-6, TNF, and IL-1b,
respectively: m-a-hIL-6 clones MQ2-13A5 and MQ2-39C3 (Biolegend);
m-a-hTNF clones MAb1 and MAb11 (BD Pharmingen); m-a-hIL-1b
clones JK1B-1 and JK1B-2 (Biolegend).
2.5. Statistical analysis
Statistical differences between groups were analyzed using
Graphpad Prism software. P values were calculated with a two-tailed
unpaired Student's t test, with *p b 0.05; ** p b 0.01; *** p b 0.001. Bar
graphs represent the mean of each data set +/− the standard error of
the mean (SEM).
3. Results
3.1. Blockade of enzymatic C1s activity does not affect C1q binding to early
or late apoptotic cells
Since C1q is regarded as a major ligand facilitating the ingestion of
AC (reviewed in [39]), we ﬁrst examined whether the C1s inhibitor
mAb, TNT003, interferes with C1q binding to AC. When we examined
C1q binding to both early (N65% AnnexinV+PI−) and late (N90%
AnnexinV+PI+) AC with added exogenous C1q but in the absence of
normal human serum (NHS), we observed little binding of C1q to
early AC (Fig. 1A), but high binding to late AC (Fig. 1B), similar to
previous studies [15,40,41]. Binding was unaffected by TNT003 pre-
treatment. Because C1q binding to AC was low in NHS (Fig. 1C, top
row), as also shown by others [15,41–43], we supplemented 10% NHS
with 15 μg/ml of puriﬁed human C1q to increase detection (Fig. 1C, bot-
tom row), and then asked whether TNT003 affected C1q binding to late
AC in the presence of other serum factors. Compared to the isotype con-
trolmAb, TNT003 preincubation did not alter the binding of C1q to early
(Fig. 1A) or late AC (Fig. 1B and C), regardless of the presence of serum.
3.2. C1s targeting prevents C3b deposition on late apoptotic cells
In the presence of serum, C3b/bi is deposited on AC, but the relative
roles of the classical, alternative, and lectin pathways have not been
fully elucidated. We therefore examined the effect of C1s inhibition on
C3b deposition on AC by incubating either early (N65% Annexin
V+PI−) or late (N90% Annexin V+PI+) AC in NHS containing either
TNT003 or isotype control mAb. Consistent with previously published
observations [42,44], little C3b deposition was observed on Annexin
V+PI− early AC (Fig. 2A), likely explained by residual complement
regulatory protein activity during early apoptosis [41], but was readily
detectable on Annexin V+PI+ late AC (Fig. 2B). We therefore assessed
the effect of TNT003-mediated C1s inhibition on C3b deposition on late
apoptotic/secondary necrotic cells. C3b deposition was detected on late
AC in the presence of NHS, but not in the absence of serum orwith heat-
inactivated serum (HI NHS; Fig. 2B). Pre-incubation of NHS with
Fig. 1.Blockade of the enzymatic C1s activity does not affect initial C1q binding to apoptotic cells. A) Early (A) (N65%AnnexinV+PI−) and late (B) (N90%AnnexinV+PI+)ACwere incubated
with serum-free media supplemented or not with puriﬁed C1q (15 μg/ml) and/or isotype control mAb (Iso C) or TNT003 (C1s inhibitor). C1q binding was monitored by ﬂow cytometry
and the results expressed asmean ﬂuorescence intensity (MFI). Data was pooled from 3 independent experiments (n= 6–7 per condition for early AC; n= 4–5 per condition for late AC;
p = NS difference with TNT003 or isotype control preincubation). C) Media containing NHS or NHS + C1q (15 μg/ml) were pre-incubated with isotype control mAb or TNT003 before
incubation with late AC. The AC were then washed, and stained with a mouse-anti-human C1q mAb for ﬂow cytometry analysis as in A. Data was pooled from 3 independent
experiments (n = 4–5 wells per condition; p = NS change with TNT003 or isotype control pretreatment).
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reduction, comparable to that seen in the absence of serum or with HI
NHS (Fig. 2B; *p b 0.05). Our results indicate that TNT003-mediated
C1s targeting does not affect initial C1q binding, whereas it does inhibit
C1s activity and downstream C3b deposition on late AC, supporting the
model that most C3b is deposited following activation of the classical
pathway [11].
3.3. C1s blockade inhibits the phagocytosis of late AC, while having a small
effect on the uptake of early AC by human phagocytes
To determine whether C1s inhibition impacts the clearance of dying
cells, we incubated ﬂuorescently labeled (CFSE+) early (Fig. 3A) and
late (3B) AC with C1q-depleted (C1qD) serum that completely lacks
classical pathway activity, or with NHS and HI NHS that were pre-
incubated with TNT003 or isotype control. When we challenged prima-
ry human macrophages (Mo) with CFSE+ early AC, C1q depletion
markedly reduced phagocytosis (60.3% +/− 5.7%), whereas TNT003
had a modest but statistically signiﬁcant inhibitory effect (Fig. 3A;24.4% +/− 6.1% versus−1.9% +/− 5.4% by TNT003 and isotype con-
trol, respectively; **p b 0.01). In contrast, C1s inhibition substantially re-
duced the uptake of late apoptotic/secondary necrotic cells (Fig. 3B;
42.1% +/− 3.1 SEM versus 1.9% +/− 7.2 SEM inhibition by TNT003
and isotype control respectively; ***p b 0.001), in a comparable manner
to C1qD serum. As expected, TNT003 did not have any inhibitory effect
on the phagocytosis of early (Fig. 3A) or late (3B) AC pre-incubatedwith
HI NHS. These results suggest that the complement dependent
clearance of secondary necrotic cells principally relies on enzymatic
activation of the classical pathway and C3b deposition, while early AC
clearance is more dependent on the opsonic capacity of C1q [15,16,
45–49].
3.4. C1s blockade does not affect the immunosuppressive capacity of early
apoptotic cells
A key consequence of phagocytosis of early AC is the suppression of
proinﬂammatory cytokine production, thus limiting the immune re-
sponse to self [11,35,36,38,50,51]. This is a characteristic of early AC,
Fig. 2. C1s targeting prevents C3b deposition on late apoptotic cells. A) Media containing no serum, NHS, or HI NHS were incubated with early AC, followed by staining with mouse-anti
human C3b mAb and ﬂow cytometry analysis. The C3b MFI values were pooled from 4 independent experiments; n = 4–6 per condition; p = NS). B) Media containing no serum,
NHS, or HI NHS were preincubated with either isotype control mAb (Iso C) or TNT003 before incubation with late AC, followed by C3b staining and ﬂow cytometry analysis. The C3b
MFI values were pooled from 8 independent experiments; n = 8–11 samples per condition; *p b 0.05).
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crease proinﬂammatory cytokine production by macrophages (Mo)
(as shown by [52] and our own unpublished observations). We per-
formed preliminary experiments to optimize the incubation period nec-
essary to assess AC-mediated suppression of proinﬂammatory
cytokines by TLR-stimulated Mo. Overnight incubation was more efﬁ-
cient compared to 2 h incubation with regards to AC phagocytosis,
with an average of 72% and 44.5% of Mo ingesting early AC following
overnight and 2 h incubation, respectively (Supplemental Fig. 1A and
B). At the 2 h time point, ~32% of non-engulfed AC were still found in
the supernatant after 4 washes with PBS (Supplemental Fig. 1C). On
the other hand, following overnight incubation, we detected only a
small number of non-phagocytosed AC in the co-culture media, ac-
counting for about 12% of the initial number of AC added, among
which ~9% progressed to secondary necrosis as monitored by trypan
blue staining. These data suggest that most apoptotic cells were cleared
by the macrophages following overnight incubation, in accordance to
data previously shown in a murine macrophage cell line [53]. To deter-
mine whether TNT003-mediated C1s blockade interfered with the im-
munosuppressive properties of early AC, we challenged primary
humanMowith the TLR4 agonist LPS, a potent inducer of proinﬂamma-
tory cytokine secretion by human Mo [54]. To prevent confounding ef-
fects from additional endotoxin and from activating FcgR-mediated
Mo activation [55], we employed endotoxin-free F(ab’)2 preparations
of both TNT003 and isotype control mAb in these assays. As also ob-
served by others [36,37], a shorter incubation time with AC (2 h in ourexperiments)was sufﬁcient to suppress proinﬂammatory cytokine pro-
duction butwe used the overnight assay as the suppressionwas optimal
at these conditions (Supplemental Fig. 1D and E). As previously shown
[35,36,38], AC addition to the Mo culture effectively inhibited the pro-
duction of the proinﬂammatory cytokines TNF-a (35.4% inhibition;
Fig. 4A) and IL-6 (52.9% inhibition; Fig. 4B), and showed a smaller yet
signiﬁcant inhibition of IL-1b production by LPS-stimulated macro-
phages (26.3% inhibition; Fig. 1C) (** p b 0.01, **p b 0.01, and
p b 0.001 by two-tailed paired Student's t test for TNF-a, IL-6, and IL-
1b, respectively). Consistent with the modest effect of TNT003 on
early AC phagocytosis (Fig. 3A), blockade of C1s activity did not attenu-
ate the immunosuppressive effects of early AC (Fig. 4).4. Discussion
Billions of dying cells need to be removed from the circulation as
well as from solid organs each day [56]. Numerous AC-binding opsonins
have been implicated in this process, among which are components of
the classical complement pathway [22,39]. The data presented here
suggest that speciﬁc mAb-mediated C1s inhibition mainly affects the
uptake of late apoptotic/secondary necrotic cells by blocking comple-
ment activation on the cell surface (N60.7% inhibition of C3b
deposition). In contrast, C1s inhibition does not cause signiﬁcant
accumulation nor affects the immunosuppressive properties of early ap-
optotic cells. This likely occurs because, under physiological conditions,
Fig. 3. C1s blockade primarily inhibits the phagocytosis of late AC,while having a small effect on the uptake of early AC by human phagocytes. A) NHS orHI NHS containing either isotype control
mAb (Iso C) or TNT003were incubatedwith early AC. The ACwere fed toM-CSF-derived humanmacrophages at a 2:1 apoptotic cell:macrophage ratio for 20min at 37 °C. AC phagocytosis
was quantiﬁed by calculating the percent inhibition of CFSEMFI of the CD14+ gatedMo population by isotype control mAb, TNT003, or C1qD serumwith respect to the untreated wells.
Datawas pooled from6 independent experimentswith NHS or HI NHS (n=12 per condition; **p b 0.01 between TNT003 and isotype control), and 3 experiments with C1qD serum (n=
6; *p b 0.05 between TNT003 and C1qD serum-mediated inhibition). B) Phagocytosis of late AC was assayed as in A. Data was pooled from 5 independent experiments (n = 6 wells per
condition; ***p b 0.001 between TNT003 and isotype control).
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swift and efﬁcient uptake and clearance of dying cells [57,58].
Lupus patients have defects in AC clearance [59,60], which lead to
secondary necrosis (late AC) with exposure of intracellular self-
antigens and spillage of inﬂammatory mediators, thus predisposing to
autoimmunity [57,58,61,62]. Our observations are consistent with pre-
vious studies showing that late apoptotic/secondary necrotic Annexin
V+PI+ cells, rather than early apoptotic Annexin V+PI- cells, activate
the classical complement pathway and show increased serum-
dependence for their phagocytic clearance [11,41,42,44]. Live cells ex-
press membrane complement regulatory proteins such as CD59, CD55,
and CD46, that protect them from complement activation and cell
lysis [63]. Apoptotic cell death is characterized by the downregulation
of surface complement regulatory proteins, allowing complement acti-
vation selectively on dying cells [64]. Themarked difference of C1s inhi-
bition on the phagocytosis of early and late AC is likely due to increased
complement activation and deposition on late apoptotic/secondary ne-
crotic cells. Indeed, CD46 downregulation was shown to increase with
time following apoptosis induction, with minimal CD46 detection 24 h
post induction [65]. In line with our results, C3 deposition [42,44] was
consistently shown to be enhanced on late apoptotic cells, suggesting
that complement activation and complement-mediated clearance
mechanisms are dominant in late stages of apoptosis/secondary necro-
sis. Importantly, since TNT003-mediated C1s inhibition leaves the bind-
ing of uncomplexed C1q to AC unaffected, C1q remains free to mediateits cascade-independent functions in both the uptake [47–49] and/or
immunosuppressive properties [15,21,66] of dying cells. For example,
C1q was shown to promote tolerance by binding to SLE immune com-
plexes and inhibiting IFN-a production by plasmacytoid dendritic cells
both directly [12] and by redirecting their uptake tomonocytes [13]. In-
deed, C1q depletion from serum showed a pronounced inhibitory effect
on the uptake of early AC compared to the modest effect seen with
TNT003 pretreatment of NHS (60.3% versus 24.4% inhibition by C1qD
and TNT003, respectively). This indicates that, despite low C1q binding,
early AC mainly rely on the known cascade-independent opsonic prop-
erties of C1q acting as a bridgingmolecule between phagocytes and ap-
optotic cells [15,16,45–49], rather than enzymatic activation of the C1
complex. In line with our observations, C1q-mediated enhancement of
efferocytosis was previously shown to be independent on the quantity
of C1q bound to dying cells [41]. However, as C1q depletion from
serum was shown to also affect the levels of other factors involved in
AC clearance such as properdin, Factor D [15] and ﬁcolin-2 [31],we can-
not exclude that lack of one or more of these other factors may have
partly affected phagocytosis in depleted serum.
4.1. Concluding remarks
Complement activation participates in the pathogenesis of a multi-
tude of different disorders including inﬂammation, autoimmunity, and
transplantation [3]. Speciﬁc targeting of C1s enzymatic activity via a
Fig. 4. C1s blockade does not affect the immunosuppressive capacity of early apoptotic cells. Early AC pre-incubatedwith NHS and isotype control (Iso C) or TNT003were added to humanMo
(4:1 AC:Mo ratio) at the same time of LPS addition (1 ng/ml). After overnight culture, supernatants were harvested and [TNF-a] (A), [IL-6] (B) and [IL-1b] (C) were quantiﬁed by ELISA
assay. Data is presented as percent [TNF-a], [IL-6], and [IL-1b] of LPS alone control well, and was pooled from 4 independent experiments (n = 4 per condition; **p b 0.01 for TNF and
IL-6 inhibition by AC; ***p b 0.001 for IL-1b by two tailed paired Student's t test. p = NS change in presence or absence of isotype control or TNT003 compared to untreated wells).
89L. Colonna et al. / Clinical Immunology 163 (2016) 84–90blocking mAb selectively inhibits the earliest step of classical pathway
activation and the downstream generation of inﬂammatory mediators
(such as C3a and C5a anaphylatoxins), while preserving a) C1q
opsonization and its downstream effects, and b) the activation of alter-
native and lectin pathways. TNT003 has previously been shown to pre-
vent antibody-driven complement activation on red blood cells [67] and
endothelial cells [68], and its humanized version, TNT009, is currently
under evaluation in healthy volunteers (ClinicalTrials.gov; ID:
NCT02120482). This strategy runs the theoretical risk of impeding AC
clearance [56]. Here, we show that pharmacological inhibition of C1s
by TNT003 had a signiﬁcant impact on secondary necrotic phagocytosis
(~42.1% inhibition), comparable to that seen with C1q depletion from
serum (40.1%). However, C1s inhibition did not impact C1q binding to
AC, and while it had a modest (~24.4%) inhibitory effect on the phago-
cytosis of early AC, their immunosuppressive properties remained
entirely unaffected. As apoptotic cells are thought to be cleared very
rapidly in vivo [28,29], C1s inhibition may represent a promising
therapeutic approach to control aberrant classical pathway activation
without affecting the immunosuppressive effects of AC clearance in
disorders without abnormalities in efferocytosis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.clim.2015.12.017.
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